In a prospective multicentre study we investigated variations in pain management used by knee arthroplasty surgeons in order to compare the differences in pain levels among patients undergoing total knee replacements (TKR), and to compare the effectiveness of pain management protocols. The protocols, peri-operative levels of pain and patient satisfaction were investigated in 424 patients who underwent TKR in 14 hospitals. The protocols were highly variable and peri-operative pain levels varied substantially, particularly during the first two post-operative days. Differences in levels of pain were greatest during the night after TKR, when visual analogue scores ranged from 16.9 to 94.3 points. Of the methods of managing pain, the combined use of peri-articular infiltration and nerve blocks provided better pain relief than other methods during the first two post-operative days. Patients managed with peri-articular injection plus nerve block, and epidural analgesia were more likely to have higher satisfaction at two weeks after TKR. This study highlights the need to establish a consistent pain management strategy after TKR

Abstract. Introduction. Adverse reactions to pain medication and pain can delay discharge after outpatient knee arthroplasty (TKA). Pharmacogenomics is an emerging tool that might help reduce adverse events by tailoring medication use based on known genetic variations in the CYP genes determining drug metabolism. This study was undertaken to evaluate whether pre-operative pharmacogenomic testing could optimize peri-operative pain management in patients undergoing total knee arthroplasty (TKA). Methods. This prospective, randomized study was performed in adults undergoing primary TKA. Patients in the experimental group underwent pre-operative pharmacogenomic evaluation and medication adjustments. Medications were not optimized for control patients. The Overall Benefit of Analgesic Score (OBAS) at 24 hours post-op was the primary outcome. Postoperative pain scores (VAS scale), total opioid use, time in recovery, and time to discharge were also compared. Results. 76 patients enrolled. 93% of patients had a poor-intermediate phenotype for at least one of four CYP genes. OBAS did not differ significantly between the two groups (4.2 control vs. 4.7 experimental; 95% CI −1.1 to 2.1) and was below the minimum clinically important difference of 2.0 points. Furthermore, there were no differences in any OBAS subscale including pain, satisfaction, or nausea. There were no differences in time in the recovery area or to discharge from hospital, or narcotic use. Conclusions. Despite many patients having a poor-intermediate phenotype for a CYP gene, pharmacogenomic testing prior to TKA and medication adjustment did not improve anesthesia or pain management outcomes, time to discharge or mean total opioid use after surgery

Aims

The purpose of this study was to use pharmacogenetics to determine the frequency of genetic variants in our total knee arthroplasty (TKA) patients that could affect postoperative pain medications. Pharmacogenetic testing evaluates patient DNA to determine if a drug is expected to have a normal clinical effect, heightened effect, or no effect at all on the patient. It also predicts whether patients are likely to experience side effects from medicine. We further sought to determine if changing the multimodal programme based on these results would improve pain control or reduce side effects.

Aims

Liposomal bupivacaine (LB) as part of a periarticular injection protocol continues to be a highly debated topic in total knee arthroplasty (TKA). We evaluated the effect of discontinuing the use of LB in a periarticular protocol on immediate postoperative pain scores, opioid consumption, and objective functional outcomes.

Aims

Single-shot adductor canal block (ACB) after total knee arthroplasty (TKA) for postoperative analgesia is a common modality. Patients can experience breakthrough pain when the effect of ACB wears off. Local anaesthetic infusion through an intra-articular catheter (IAC) can help manage breakthrough pain after TKA. We hypothesized that combined ACB with ropivacaine infusion through IAC is associated with better pain relief compared to ACB used alone.

Introduction. Opioid abuse is a national epidemic. Traditional pain management after total knee arthroplasty (TKA) relied heavily on opioids. The evidence that in-hospital multimodal pain management (MMPM) is more effective than opioid-only analgesia is overwhelming. There has been little focus on post-discharge pain management. The purpose of this study was to determine whether MMPM after TKA could reduce opioid consumption in the 30-day period after hospital discharge. Methods. This was a prospective, two-arm, comparative study with a provider cross-over design. The first arm utilized a standard opioid-only (OO) prn regimen. The second arm utilized a 30-day MMPM regimen (standing doses of acetaminophen, metaxalone, meloxicam, gabapentin) and opioid medications prn. Surgeons crossed over protocols every four weeks. The primary outcome measure was VAS pain score. Secondary outcome measures included morphine milligram equivalents (MME) consumed, failure of the protocol, and manipulation under anesthesia (MUA). A pre-hoc power analysis was performed for the primary outcome measure and an intent-to-treat analysis was done utilizing a longitudinal mixed model. Results. There were 43 patients in the OO cohort and 39 patients in the MMPM cohort. There was no difference in the baseline demographics or preoperative scores (p=0.94). There was no clinically meaningful difference in VAS score between the two groups at any time. The average opioid consumption at 30-days was 469 and 344 MME's for the OO and MMPM cohorts, respectively (p=0.026). 19/43 (44.2%) patients in the OO cohort failed vs. 4/39 (10.3%) in the MMPM cohort (p=0.002). There was 1 MUA in the OO and none in the MMPM cohort (p=0.338). Discussion. A 30-day post-discharge multimodal pain regimen reduced opioid use after TKA. Opioid-only regimens are at an increased risk of failure to control pain. As a result of this study, multimodal pain management after hospital discharge is standard at our institution

Summary. Despite adoption of robust clinical pathways, narcotic administration within the inpatient setting is highly variable and may benefit from the implementation of standardized multi-modal pain management protocols. Introduction. Total knee arthroplasty (TKA) candidates have historically received high doses of opioids within the perioperative period for the management of surgical pain. Healthcare systems have responded by improving opioid prescribing documentation and implementing narcotic-sparing pain protocols into TKA integrated care pathways (ICP). Despite these efforts, there are few technological platforms specifically designed to measure the narcotic burden immediately postoperatively. Here we present an early iteration of an inpatient narcotic administration-reporting tool, which normalizes patient narcotic consumption as an average daily morphine-milligram-equivalence (MME) per surgical encounter (MME/day/encounter) among total knee arthroplasty (TKA) recipients. This information may help orthopaedic surgeons visualize their individual granular inpatient narcotic prescribing habits individually and compared to other surgeons, while taking into consideration patient and procedure specific variables in order to optimize use and curtail unnecessary narcotic prescriptions. Material and Methods. A query of our electronic data warehouse, was performed for patients undergoing elective primary TKA between January 1, 2016 to April 30, 2017. Patients undergoing revision or bilateral procedures were excluded. Patient demographics, inpatient and surgical factors, and inpatient narcotic administration were retrieved. Narcotic type, route and dose were converted into average total Morphine Milligram Equivalents per patient for each post- operative day (figure 1). These MME/day/encounter values were subsequently used determine mean and variance of narcotics prescribed by individual surgeons. A secondary analysis of regional distribution of inpatient narcotic consumption was determined by patient's zip codes. Results. In total, 20 surgeons performed 3,666 primary TKAs. The institutional average narcotic dose administered for a single surgical encounter was 34.45±60.06 MME/day (Figure 1). Average surgeon narcotic prescribing ranged from 18.54 to 42.84 MME/day. Similarly, intra-surgeon variability of narcotic prescribing habits varied from ±20.23 to ±129.02 MME/day. Further visualization of patient breakdown did not demonstrate a trend towards increased narcotic administration or variability for surgeons when compared to race or insurance type. Discussion. Our results suggest that narcotic administration following primary TKA demonstrated a substantial degree of intra-institutional variability for individual surgeons despite the use of standardized clinical pathways. TKA candidates may benefit from the implementation of a more rigid standardization of multi-modal pain management protocols that can control pain while minimizing the narcotic burden. Studies designed to analyze the variability of narcotic use in the post-operative period and determine strategies to minimize inappropriate variation are needed. For any figures or tables, please contact authors directly

Aims. Adductor canal block (ACB) has emerged as an alternative to femoral nerve block (FNB) for analgesia after total knee arthroplasty (TKA). The optimal duration of maintenance of the ACB is still questionable. The purpose of this study was to compare the analgesic benefits and physiotherapy (PT) outcomes of single-shot ACB to two different regimens of infusion of the continuous ACB, 24-hour and 48-hour infusion. Patients and Methods. This was a prospective, randomized, unblinded study. A total of 159 American Society of Anesthesiologists (ASA) physical status I to III patients scheduled for primary TKA were randomized to one of three study groups. Three patients did not complete the study, leaving 156 patients for final analysis. Group A (n = 53) was the single-shot group (16 female patients and 37 male patients with a mean age of 63.9 years (. sd. 9.6)), group B (n = 51) was the 24-hour infusion group (22 female patients and 29 male patients with a mean age of 66.5 years (. sd. 8.5)), and group C (n = 52) was the 48-hour infusion group (18 female patients and 34 male patients with a mean age of 62.2 years (. sd. 8.7)). Pain scores, opioid requirements, PT test results, and patient-reported outcome instruments were compared between the three groups. Results. The proportion of patients reporting severe pain, defined as a pain score of between 7 and 10, on postoperative day number 2 (POD 2) were 21% for the single-shot group, 14% for the 24-hour block group, and 12% for the 48-hour block group (p = 0.05). Cumulative opioid requirements after 48 hours were similar between the groups. Functional outcomes were similar in all three groups in POD 1 and POD 2. Conclusion. There was no clear benefit of the 24-hour or 48-hour infusions over the single-shot ACB for the primary endpoint of the study. Otherwise, there were marginal benefits for keeping the indwelling catheter for 48 hours in terms of reducing the number of patients with moderate pain and improving the quality of pain management. However, all three groups had similar opioid usage, length of hospital stay, and functional outcomes. Further studies with larger sample sizes are needed to confirm these findings. Cite this article: Bone Joint J 2019;101-B:340–347

Aims

In the last decade, perioperative advancements have expanded the use of outpatient primary total knee arthroplasty (TKA). Despite this, there remains limited data on expedited discharge after revision TKA. This study compared 30-day readmissions and reoperations in patients undergoing revision TKA with a hospital stay greater or less than 24 hours. The authors hypothesized that expedited discharge in select patients would not be associated with increased 30-day readmissions and reoperations.

Aims

To investigate the impact of consecutive perioperative care transitions on in-hospital recovery of patients who had primary total knee arthroplasty (TKA) over an 11-year period.

Aims

In cases of severe periprosthetic joint infection (PJI) of the knee, salvage procedures such as knee arthrodesis (KA) or above-knee amputation (AKA) must be considered. As both treatments result in limitations in quality of life (QoL), we aimed to compare outcomes and factors influencing complication rates, mortality, and mobility.

Introduction. Enhanced pain and rehabilitation protocols have significantly improved patient recovery following primary TKR. Little has been written on how the protocols have affected the revision TKR patient. We report on a matched group of revision and primary TKR patients treated with the identical pain and rehab program. Materials and Methods. 40 aseptic RTKR patients who underwent a full femoral and tibial revision were matched by age, sex, and BMI to a group of patients who underwent a cemented tri-compartmental primary TKR. All revision knees had uncemented stemmed femurs and tibias. All 40 patients had either a metaphyseal sleeve on either the femur or tibia or both. Patients in both groups were treated with an identical post op pain protocol (Spinal anesthetic, local infiltrative analgesia and multimodal oral pain management along with rapid rehabilitation). All patients were mobilized on POD1 and allowed weight bearing as tolerated. Patients were followed for a minimum of 1 year. KSS at 6 weeks and 1 year were recorded for both groups. Results. There was no significant difference in length of stay between the RTKR and the primary TKR (1.2 days versus 1.1 days). Average oral morphine equivalents used during the hospitalization was 38 for the RTKR and 42 for the primary group. There was 1 readmission in each group: GI distress in the RTKR and urinary retention in the primary group. There no were reoperations, wound healing problems, identified thromboembolic events or manipulations under anesthesia in either group. KSS for the RTKR group averaged 87.3 at 6 weeks (range 45 to 99) and 89.1at minimum 1 year (range 52 to100). KSS for the primary group averaged 89.9 (range 71 to 100) at 6 week follow-up and 93.2 (range 54 to 100) at minimum follow-up. Range of motion at final follow up averaged1.2 (0–10) to 114.1 (55–135) for the RTKR group and 1 (0–8) to 121.3 (85–140) for the primary group. Conclusion. Despite more complex surgery in the revision total knee patient, enhanced pain and rehabilitation protocols have enabled the RTKR patient to have a similar recovery and outcome compared to the primary TKR patient. For figures, tables, or references, please contact authors directly

Introduction. Even as the outcomes of primary total knee arthroplasty (TKA) continue to improve, there remain increasing concerns about pain control after surgery and prolonged narcotic use. Cryoneurolysis has been demonstrated to reduce osteoarthritis knee pain for up to 90 days. We hypothesized that postoperative narcotic use could be reduced following preoperative cryoneurolysis of the superficial genicular nerves. Methods. Primary TKA patients were randomized into either a control or cryoneurolysis treatment group. Both followed the same preoperative, intraoperative, and postoperative pain management protocol, except the treatment group had cryoneurolysis of their superficial genicular nerves 3–7 days prior to surgery. All patients were prescribed 40 narcotic pills at discharge and pills were counted at 72 hours and at 2,6, and 12 weeks postoperatively. The primary endpoint was daily morphine equivalent (DME) based on pill count and secondary endpoints were changes in pain and Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS, Jr.) scores. Results. Per-protocol results demonstrated that the DME for the treatment group was significantly lower at 72 hours (10.9 mg vs. 14.9 mg, p=0.0389), 6 weeks (4.2 mg vs. 5.9 mg, p=0.0186) and 12 weeks (2.4 mg vs 3.4 mg p=0.0234). Overall, there was a 29% reduction in the DMEs over the entire 12-week postoperative period. Only 14% of the treatment group consumed opioids past 6 weeks compared to 44% of the control group (p=0.0005). The treatment group demonstrated a greater reduction in pain scores from baseline at 72 hours and 12 weeks. The treatment group also showed significant improvements in KOOS Jr. scores compared to the control group at all timepoints. Conclusions. The results demonstrate that preoperative cryoneurolysis can reduce opioid consumption after TKA. The early cessation of opioid consumption is especially encouraging given the association of prolonged narcotic use with increased complications following surgery. Preoperative cryoneurolysis should be considered as part of a multimodal protocol to reduce opioid consumption and pain and improve function after TKA. For figures, tables, or references, please contact authors directly

Introduction. Pharmacogenetics evaluates a patient's DNA to determine if a particular drug is expected to have a normal clinical effect, heightened effect, or no effect at all on a patient. It may also predict which patients are most likely to experience side effects from the medications. The purpose of this study was to use pharmacogenetic testing to determine how frequently total knee arthroplasty (TKA) patients have genetic variants to standard postoperative pain medications. We further sought to determine if changing the multimodal program based on these results would improve pain control and reduce side effects. Methods. In this prospective, randomized study, buccal cheek swab samples were collected from 31 primary TKA patients. Pharmacogenetics testing was performed on the samples to examine genetic variants in genes OPRM1, CYP1A2, CYP2B6, CYP2C19, CYP3A4, CYP2C9, and CYP2D6. These genes affect the pharmacodynamics and pharmacokinetics of NSAIDs and opioids. We examined the frequency of a genetic variant to one of the multimodal medications we prescribe including celecoxib, hydrocodone, and tramadol. Subjects included 9 men and 22 women. Patients were randomized to one of two groups: the control group received the standard postoperative pain regimen; the study group received a customized regimen based on the pharmacogenetic results. For the first 10 postoperative days patients recorded pain scores, amount of pain medication taken, and any side effects experienced. Results. Genetic variations to one or more medications in our standard postoperative pain management protocol occurred in 13 of the 31 patients (42%). 8 patients (26%) had a variation of gene CYP2C9 affecting celecoxib. 11 patients (35%) had a variation of gene OPRM1 and/or CYP2D6 affecting the response to hydrocodone. 4 patients (13%) had a variation of gene CYP2D6 that altered their response to tramadol. Of the 31 patients tested, only 18 (58%) had no genetic variants related to the pain medications we routinely prescribe. 8 patients (26%) had variants affecting more than one of the medications. (Table 1, below) Both the average pain levels and morphine equivalents consumed in the first 10 days were higher in the control group than in the study group. Conclusion. 42% of patients in this study demonstrated a pharmacogenetic variant to one of the commonly used multimodal pain medications. Our early data suggests that customizing pain regimens based on this information can help reduce pain and the amount of pain medication used postoperatively. For figures, tables, or references, please contact authors directly

Introduction. Multimodal pain management strategies are now commonplace in perioperative management of total knee arthroplasty (TKA), although controversy remains regarding the role of adductor canal blocks (ACB) in this algorithm. Proposed benefits include theoretical decreased role of perioperative narcotic pain medication, improved function with physical therapy postoperatively, shorter duration of hospital stay and improved patient satisfaction. Those opposed cite increased cost and risk of complications including inadvertent motor blockade. The purpose of this study was to independently evaluate the effect of adductor canal block on short-term post-operative outcomes including (1) length of stay (LOS), (2) post-operative narcotic utilization, and (3) function with physical therapy in the era of modern TKA. Methods. Our institutional database was utilized to retrospectively identify a cohort of consecutive patients from January 2014-January 2018 who had undergone unilateral primary TKA with a single surgeon utilizing a preoperative single-shot ACB in addition to a standardized multimodal pain regimen versus those that only received the same multimodal pain regimen (no-ACB). The primary reason that a patient did not receive a preoperative block was lack of availability of the block team The time period of interest was selected based on the implementation of our current pain protocols. The multimodal pain regimen consists of: preoperative Tylenol, a periarticular injection intraoperatively including 0.5% Marcaine and Toradol, IV Toradol postoperatively, Percocet, Celebrex and IV narcotic medication for breakthrough pain. These 2 groups were compared utilizing independent sample T-tests with primary endpoints of interest being LOS (in total hours and as %day 1 discharges (%POD1)), distance ambulated with inpatient therapy on postoperative day 1, and inpatient narcotic use as measured in morphine equivalents per hour. A sub-cohort of patients with adductor canal block was then selected based on time of surgery to control for time of discharge and hours in the hospital to isolate the effect of the block. Results. There were 624 patients in the ACB group, with a mean age of 64.5 years. The group without ACB consisted of 69 patients, with a mean age of 67.2 years. The no-ACB group was slightly older (p=0.024) but not significantly different in terms of BMI (32.6 vs 31.7, p=0.291). The ACB group ambulated significantly further with inpatient therapy on postoperative day 1 (75.8 vs 59.9 ft, p=0.008), had a shorter LOS in both total hours and %POD1 (34.8 vs 40.6 hours, p=0.01, 83% vs 66.6%, p=0.01). Finally, there was no significant difference between the 2 groups in narcotic utilization postoperatively (2.361 vs 2.0 97, p=0.088). The subcohort of patients that had adductor canal blocks who had their surgery in the afternoon (n=157) were compared to the remainder of the patients to control for LOS data and no statistical differences were seen in either total hospital hours or %POD1. Conclusion. Adductor canal blocks did not decrease post-operative pain medication utilization. The modest improvement in distance ambulated with therapy on POD1 (16 ft) and length of stay (16% greater POD1 discharges) of hospitalization may not support the cost effectiveness of this intervention

Aims

This study used an artificial neural network (ANN) model to determine the most important pre- and perioperative variables to predict same-day discharge in patients undergoing total knee arthroplasty (TKA).

Aims

Manipulation under anaesthesia (MUA) remains an effective intervention to address restricted range of motion (ROM) after total knee arthroplasty (TKA) and occurs in 2% to 3% of primary TKAs at our institution. Since there are few data on the outcomes of MUA with different anaesthetic methods, we sought to compare the outcomes of patients undergoing MUA with intravenous (IV) sedation and neuraxial anaesthesia.

Aims

Although total knee arthroplasty (TKA) is a highly successful procedure, about 20% of patients remain dissatisfied postoperatively. This proportion is derived from dichotomous models of the assessment of surgical success or failure, which may not reflect the spectrum of outcomes. The aim of this study was to explore differing responses to surgery, and assess whether there are distinct groups of patients with differing patterns of outcome.

Pain is the main indication for performing total knee replacement (TKR). In most patients after TKR there is an improvement, but a few continue to have pain. Generally, the cause of the pain can be addressed when it is identified. However, unexplained pain can be more difficult to manage because revision surgery is likely to be unrewarding in this group. In our study of 622 cemented TKRs in 512 patients with a mean age of 69 years (23 to 90) treated between January 1995 and August 1998, we identified 24 patients (knees) with unexplained pain at six months. This group was followed for five years (data was unavailable for 18 knees) and ten patients (55.5%) went on to show an improvement without intervention. In the case of unexplained pain, management decisions must be carefully considered, but reassurance can be offered to patients that the pain will improve in more than half with time

Aims

Enhanced perioperative protocols have significantly improved patient recovery following primary total knee arthroplasty (TKA). Little has been investigated the effectiveness of these protocols for revision TKA (RTKA). We report on a matched group of aseptic revision and primary TKA patients treated with an identical pain and rehabilitation programmes.